April 08, 2024

Journal of the American College of Cardiology

  1. Home
  2. Media Center

Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Nonobstructive Hypertrophic Cardiomyopathy: Phase 2 Study

https://doi.org/10.1016/j.jacc.2024.03.387

Explore further

April 08, 2024

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

April 08, 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

April 08, 2024

Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM

March 25, 2024

Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

Back Continue